The U.S. Food and Drug Administration (FDA) has approved Dysport, a "next generation" acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement of the appearance of moderate to severe glabellar or frown lines between the brows. Dysport, marketed by Medicis Aesthetics, the distributers of Restylane and Perlane, has been used in over two million treatments worldwide in 27 countries.

Studies and patient reports have shown that Dysport may last up to eight months compared to the four to six months that Botox is effective, according to the company.It has been evaluated for safety and efficacy in clinical studies which included approximately 3,000 patients and 10,000 injections at more than 80 study sites in the U.S.